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ABSTRACT
BMP2 and BMP7, which use bovine Achilles tendon–derived absorbable collagen sponge and bovine bone collagen as scaffold,
respectively, have been approved as bone graft substitutes for orthopedic and dental indications. Here, we describe an
osteoinductive autologous bone graft substitute (ABGS) that contains recombinant human BMP6 (rhBMP6) dispersed within
autologous blood coagulum (ABC) scaffold. The ABGS is created as an injectable or implantable coagulum gel with rhBMP6 binding
tightly to plasma proteins within ﬁbrin meshwork, as examined by dot-blot assays, and is released slowly as an intact protein over 6
to 8 days, as assessed by ELISA. The biological activity of ABGS was examined in vivo in rats (Rattus norvegicus) and rabbits
(Oryctolagus cuniculus). In a rat subcutaneous implant assay, ABGS induced endochondral bone formation, as observed by histology
and micro-CT analyses. In the rabbit ulna segmental defect model, a reproducible and robust bone formation with complete
bridging and restoration of the defect was observed, which is dose dependent, as determined by radiographs, micro-CT, and
histological analyses. In ABGS, ABC scaffold provides a permissive environment for bone induction and contributes to the use of
lower doses of rhBMP6 compared with BMP7 in bovine bone collagen as scaffold. The newly formed bone undergoes remodeling
and establishes cortices uniformly that is restricted to implant site by bridging with host bone. In summary, ABC carrier containing
rhBMP6 may serve as an osteoinductive autologous bone graft substitute for several orthopedic applications that include delayed
and nonunion fractures, anterior and posterior lumbar interbody fusion, trauma, and nonunions associated with neuroﬁbromatosis
type I. © 2018 American Society for Bone and Mineral Research.
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Introduction
Bone heals spontaneously upon fracture by recapitulating thecellular events associated with embryonic bone develop-
ment,(1–3) except when compromised by smoking, use of steroids,
pseudoarthrosis in NF-1 patients, and osteoporosis.(1,4,5) The large
bone defects caused by tumors, trauma, congenital disorders, and
infection also fail to heal and over time become a nonunion
representing challenging issues in orthopedic medicine and a
burden for the health care system.(1,6) In approximately 10% of
cases, bone fractures heal slowly or fail to heal and require
additional medical interventions.(7,8) For example, tibial nonunion
can potentially lead to the loss of the function or even loss of
limb.(9) The medical need in this clinical area warrants new and
effective therapies to be developed and introduced in clinical
practice.
Autograft is a gold standard to promote bone healing and
restore function for segmental long bone defects, delayed and
nonunion fractures, and spinal fusion procedures. The availabil-
ity of autologous bone tissue, limited in quantity and morbidity,
is associated with harvested site, which demands an alternative
to autograft bone.(10–12) Allogenic demineralized bone matrix
(DBM) has been used widely as an option to induce new bone
formation because it provides osteoinductive signals and
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osteoconductive substratum.(13–15) Advances made in the
isolation of bone morphogenetic proteins (BMP) from DBM(16)
and subsequently the identiﬁcation of the corresponding
genes(17,18) allowed the production of recombinant human
BMPs in promoting fracture healing at compromised set-
tings.(19–21) Recombinant BMP2 soaked in absorbable collagen
sponge (InFuse) and recombinant BMP7 combined with bovine
bone collagen (OP1-Putty) have been approved as biologic bone
graft substitutes to bridge the gap and restore delayed and
nonunion fractures.(22–24)
BMP alone cannot form bone unless it is delivered with an
appropriate scaffold and responding cells are available in a
permissive environment.(25–30) Studies thus far have used
animal-derived collagens as scaffold for BMP2 and BMP7 in
approved products and collagens, synthetic calcium phosphate-
based ceramics, and precalciﬁed cellulose matrix as scaffolds in
preclinical studies.(31–33) In clinical studies, rhBMP2 containing
collagen has been used in reconstruction of mandibular bone
defects(34,35) and delayed diaphysis fractures. Evaluation of
rhBMP2 containing ceramic-collagen composite device in
posterolateral lumbar fusion (PLF), however, has not met
primary endpoint and failed to get an FDA approval. This
device was also reported to have unwanted side effects likely
attributed to the use of a high dose of rhBMP2 and its weak
binding to collagen-ceramics.(6,36–38)
Here we describe an autologous bone graft substitute (ABGS)
that is composed of recombinant human BMP6 (rhBMP6)
combined with autologous blood coagulum (ABC) to guide the
formation of new bone to promote bone healing in a large
diaphysis segmental defect and bridge the gap. ABC circum-
vents the use of animal-derived collagen, limiting possible
inﬂammatory processes due to its autologous nature, provides
functional and physiological carrier for rhBMP6, and offers a
ﬂexibility to mold to the desired shape, thus facilitating its use
within different anatomical structures.(9) We also describe the
method of formulation using ABC and rhBMP6, binding and
release characteristics of rhBMP6 from plasma proteins, and
rheological properties for in vivo bone-inducing activity in rat
subcutaneous implants and rabbit critical size ulna defect.(39)
The preclinical data generated represent a solid foundation to
progress the ABGS toward further stages of drug development
and its use in human orthopedic indications.
Materials and Methods
Recombinant human BMPs
The manufacturing process for rhBMP6 was developed and is
conducted by Genera Research (Kalinovica, Croatia). Engi-
neered Chinese Hamster Ovary (CHO) cell line was used to
produce and purify rhBMP6 from the media using heparin
afﬁnity and hydrophobic interaction chromatography,
followed by the reverse phase HPLC. It was then lyophilized
and stored at 20°C in vials containing 0.5mg >99% pure
rhBMP6. rhBMP2 and rhBMP7 used in in vitro experiments
were from R&D Systems (Abingdon, UK). rhBMP7 for in vivo
experiments was used as OP-1 Putty commercial device
(Ossigraft) for human use.
Mouse C2C12-BRE-Luc reporter gene assay
The activity of rhBMP6was determined inmouse C2C12-BRE-Luc
BMP reporter cell assay, stably transfected with a reporter
plasmid consisting of a BMP response element (BRE) from the
Id-1 promoter fused to a luciferase reporter gene (kindly
provided by Dr Gareth Inman).(40) To measure the luciferase
activity, 20mL of the cell lysate was added to 100mL luciferase
assay reagent (Promega, Madison, WI, USA) and luminescence
was then quantiﬁed by Wallac Victor luminometer (PerkinElmer,
Waltham, MA, USA).
Formulation of rhBMP6 within ABC
Blood samples were collected from rabbit marginal ear veins
into tubes without anticoagulant substance in a volume of
1.5mL. rhBMP6 was added into the blood in the amounts of
25mg, 50mg, and 100mg with 50mM concentration of calcium
chloride and mixed by rotating the tubes. ABCþ rhBMP6 were
prepared in a syringe and left at room temperature to coagulate
for 60 to 90 minutes. The liquid portion (serum) was removed
and the homogeneous, cohesive, injectable andmalleable ABGS
gel was ready for use.
rhBMP6 characterization and release studies
For rhBMP6 identiﬁcation and characterization, lyophilized
protein samples were subjected to SDS-PAGE electrophoresis,
transferred to the nitrocellulose membrane, and analyzed by
Western blot using the rhBMP6-speciﬁc monoclonal antibody
(available in the rhBMP6 DuoSet ELISA kit, R&D Systems, DY507).
To demonstrate rhBMP6 stability in the coagulum after ABGS
formation, ABGS was homogenized 60 and 90 minutes after
preparation in 2% SDS, insoluble particles were removed by
centrifugation, and supernatants were analyzed byWestern blot
using the same rhBMP6-speciﬁc antibody.
For determination of the release proﬁle of rhBMP6 from the
ABGS, rhBMP6 was added to the blood in two concentrations, 2
and 5mg/mL. After the coagulum was formed, it was placed in
the basal medium and the release proﬁle of the rhBMP6 was
determined during a period of 14 days. The medium was
changed every 2 days, and samples of medium for rhBMP6
measurement were collected on days 1, 3, 5, 8, 10, and 12 after
ABGS formation. rhBMP6 released into the medium was
measured by the commercially available rhBMP6-speciﬁc ELISA
(R&D Systems, DY 507).
Binding affinity of rhBMP6 for plasma proteins
Autologous ﬁbrinogen concentrate (FC) was prepared from
human plasma, obtained from healthy volunteers. rhBMP6 was
radiolabeled with radioactive technetium (99mTc) using the
IsoLink Kit Mallinckrodt (Covidien Pharmaceuticals; gift from
Dr Hector H Knight). The binding afﬁnity of 99mTc-labeled
rhBMP6 to FC and other extracellular matrix (ECM) molecules,
including ﬁbrinogen, albumin, thrombin, heparan sulfate
proteoglycan, collagen I and IV, as well as the retention of
BMP6 in the plasma sample added into the blood before
precipitation, was semiquantitatively veriﬁed.(41) Brieﬂy, 1mL
of human blood (healthy volunteers) was drawn into a 2mL
syringe and, using a syringe connector, blood, CaCl2, and
200mL of 99mTc-rhBMP6 were mixed and left at room
temperature over 90 minutes in the 2mL syringe. After 90
minutes, each ABC was expelled from the syringe and the
syringe was washed with 2mL of 2% SDS and the wash was
pooled together. Radioactivity of the samples was measured
after a 2-hour incubation period using a gamma counter and
was expressed as counts per minute (cpm). All values were
corrected for the half-life factor of 99mTc.
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Testing of ABC biomechanical parameters
For evaluation of ABC biomechanical properties, forward
extrusion test (FET) and cut test were developed and validated
using Texture Analyzer TA.HD Plus (Texture Technologies,
Hamilton, MA, USA).(9) Sixteen samples were initiated from
each individual blood sample; 8 for each of the tests. Of these, 5
were used to investigate the effect of coagulation time on ABC
biomechanical properties (ie, standing at room temperature for
30, 45, 60, 75, or 90 minutes); 1 to investigate the effect of
hemolysis, which was induced by vigorous shaking (tested after
60 minutes); and 2 to investigate the effect of different CaCl2
concentrations (high 15mM and low 1mM) after 30 and 60
minutes. Overall, 9 different healthy donors (including bothmen
[n¼ 7] andwomen [n¼ 2]) contributedwith 15 blood samples in
total. In both tests, stiffness, elasticity, and work (required for
forward extrusion or cutting, respectively) were determined. The
effect of time was estimated by comparing values at 30minutes,
45 minutes, and 60 minutes to each other (30 to 60 minutes is
the anticipated coagulum formation time) and by comparing
values at 75 and 90 minutes to the average for 30 to 60 minutes
to evaluate changes in ABGS properties after 60 minutes. The
effect of blood shaking (hemolysis) was estimated by comparing
the properties with and without vigorous shaking at 60minutes.
Evaluation of time effect and the CaCl2 effect included multiple
comparisons. The effect of CaCl2 was estimated by comparing
time-averaged values between coagula formed with 0 (no), 1
(low), or 15 (high) mM CaCl2. General linear mixed models were
ﬁtted using SAS 9.3 (SAS Institute, Cary, NC, USA).
Animal models
The number of rats in s.c. bone formation assays was determined
based on a well-known ectopic bone formation cascade in time,
as previously described.(16,42) The number of rabbits per
experimental group was determined by well-characterized
percent of CSD bone repair in time, as previously described.(39)
In brief, using general linear mixed models (GLMMs) with
restricted maximum likelihood (REML) estimation to produce
time-averaged difference between groups and with using four
repeated assessments and assuming variability around 20% at
each time point, autocorrelation 0.6, and autoregressive
covariance structure, 7 animals per group per time point
provide 80% power to detect such a difference at a two-sided
a¼ 0.05. Because there was no healing of the defect in the
control animals (variability¼ 0%), we applied the 3R principle
and decreased the number of animals to 5 per each dose group
with a possibility of gradually increasing the number of rabbits
up to 7 per group, if applicable.
Rat subcutaneous implant assay
Assay was performed on 12-week-old male Sprague Dawley
laboratory rats (body weight 320 to 350 g). Laboratory animals
were housed in polysulfonic cages in conventional laboratory
conditions at 20°C to 24°C, relative humidity of 40% to 70%,
and noise level 60 dB. Standard GLP diet and fresh water was
provided ad libitum, without environmental enrichment.
Animal care was in compliance with SOPs of animal facility;
the European convention for the protection of vertebrate
animals used for experimental and other scientiﬁc purposes
(ETS 123).
rhBMP6 osteogenic activity was tested at different doses in
the rat subcutaneous assay, as previously described.(16,42) ABC
was prepared from 0.5mL of rat full blood, which was mixed
with an appropriate amount of rhBMP6 and left for 60minutes to
coagulate in a 1mL syringe. After removing the serum, 370mL of
the ABGS was implanted. The osteogenic response of rhBMP6
doses (2.5mg, 5mg, 10mg, and 20mg per mL blood) was tested
in two rats for each dose, as previously described.(14,43) Brieﬂy, a
small pocket was created under the skin in the axial regions to
implant ABC preparedwith rhBMP6. The ABCwas implanted and
sealed with a single suture to the fascia and three sutures for the
skin. To analyze ectopic bone formation, animals were scanned
using the 1076 micro-CT device (SkyScan, Bruker microCT,
Kontich, Belgium) 14 days after implantation. Ectopic bone
formation was observed in all groups of animals and was
quantiﬁed by micro-CT analysis.
The neutrophil inﬁltration was determined using naphtol AS-
D chloroacetate esterase staining (Sigma, St. Louis, MO, USA) on
histological sections. Neutrophils were counted in the vicinity
and inside ABGS using an ocular grid. Neutrophil accumulation
was expressed as number of neutrophils per mm2 in two
implants from 4 rats at day 3 after implantation. Implants
contained 20mg rhBMP2/300mg bovine Achilles tendon–
derived absorbable collagen sponge; 20mg rhBMP7/300mg
bovine bone collagen carrier; and 20mg rhBMP6/300mL ABC. In
addition, neutrophil activity was determined at day 3 after
implantation by myeloperoxidase activity (MPO), as previously
described.(44) Implants (two from4 rats) were extracted in 50mM
KPO4 buffer, pH 6.0, homogenized for 10 minutes, sonicated for
5 minutes, and ﬁnally the lysate was centrifuged for 60 minutes
at 20,000g.
The differential sensitivity to increasing concentration of
Noggin was tested in C2C12 cells transfected with BRE-Luc
reporter, in which rhBMP6 (5mg) was more resistant to noggin-
mediated inhibition compared with rhBMP7 (5mg). Recombi-
nant human Noggin was obtained courtesy of Dr Aris
Economides (Regeneron Corp., Tarrytown, NY, USA).
Rabbit ulna segmental defect model
Study protocols were conducted in male laboratory rabbits
(Oryctolagus cuniculus), New Zealand strain, 10 weeks old, with
health certiﬁcate, body weight from 2.3 to 2.5 kg. Animal facility
is registered by Directorate for Veterinary; reg. no. HR-POK-001.
An approval for the animal studies was given by the Directorate
for Veterinary and Food Safety, Ministry of Agriculture, Republic
of Croatia (approval no. 525-10/0255-14-3). Rabbits were
acclimated for 5 days and randomly assigned to their respective
treatment group. Animals were housed by standard rabbit cages
in conventional laboratory conditions at the temperature of
18°C to 22°C, relative humidity of 50% to 70%, ﬂuorescent
lighting provided illumination 12 hours per day, and noise level
was 60 dB. Standard GLP diet (Mucedola srl, Milan, Italy),
bedding, and environmental enrichment were available and
fresh water was provided ad libitum. Animal care was in
compliance with SOPs of registries Croatian Animal facility HR-
POK-001; using 3R principle, pain and suffering were minimized
during the experiment. European convention for the protection
of vertebrate animals was used for experimental and other
scientiﬁc purposes (ETS 123).
In the critical size ulna defect experiments, rabbits were
prepared as described(14,39,45) and treatedwith rhBMP6 amounts
to conﬁrm previous rhBMP6 efﬁcacy results. Brieﬂy, after
acclimatization period, enroﬂoxacin (10mg/kg) was given to
the animals by intramuscular injection 1 day before operation
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and then 10 days after surgery. Before the surgery, blood was
collected from rabbit marginal ear veins into tubes without
anticoagulant substance. ABC was prepared 60 and 90 minutes
before implantation from 1.5mL of blood mixed with an
appropriate volume of rhBMP6. Animals were randomly divided
into four groups (n¼ 5 each): A) control, defect ﬁlled with ABC
only; B) defect ﬁlled with ABCþ rhBMP6 (25mg/mL); C) defect
ﬁlled with ABCþ rhBMP6 (50mg/mL); and D) defect ﬁlled with
ABCþ rhBMP6 (100mg/mL). In another experiment (n¼ 5 per
group), ABGS (1.5mL ABCþ rhBMP6 (100mg/mL) was compared
with collagen (150mg)þ rhBMP7 (100mg/100mg;) at weeks 2
and 8 after implantation.
Each animal was premedicated with a mixture of ketamine
50mg/kg, acepramazine 1mg/kg, and xylazine 5mg/kg.
Anesthesia was maintained using a mixture of 1% to 1.5%
isoﬂurane and oxygen deliver by mask. A lateral incision,
approximately 2.5 cm in length, was made, and the tissues
overlying the ulna were dissected (skin and musculature). A
segment of the ulna measuring 17mm (large defect) was
removed and the device was implanted into the defect site, with
the radius left intact for mechanical stability, without use of
internal or external ﬁxation devices, as previously described.(9)
Radiological images of the right forelimb were taken immedi-
ately after surgery and during 23-week bone healing period.
During the experiment, there were no adverse effects. Rabbits’
euthanasia was conducted after sedation, premedication of
3mg/kg xylapane, and 20mg/kg ketamine i.m. and administra-
tion of T61 (1mL/kg) intrapulmonary.
Radiography
To monitor the critical size defect healing, X-rays were taken at
weeks 6, 9, 13, 16, 19, and 23 after surgery. All obtained
radiographs from rabbit bones were interpreted and scored
using a radiographic grading score system(46,47) by a surgeon
and a radiologist blinded to the treatment protocol and
postoperative interval. Radiographic grading scores (from 0 to
6) were as follows: 0, no change from immediate postoperative
appearance; 1, trace of radio-dense material in defects; 2,
ﬂocculent radio density with spots of calciﬁcation and no defect
bridging; 3, defect bridged at least one point with material of
nonuniform radio density; 4, defect bridged in medial, and
lateral sides with material of uniform radio density (cut ends of
cortex remain visible); 5, same as grade 3, at least one of four
cortices obscured by new bone; 6, defect bridged by uniform
new bone, cut ends of cortex not found.
Micro-CT quantification
In subcutaneous rat assay, bone formation was scanned in vivo
after 14 days using SkyScan 1076 micro-CT device (SkyScan/
Bruker) at 18mm resolution, as previously described.(48,49)
Scanning parameters were 50 kV/200mA, 0.5mm aluminum
ﬁlter, 0.8° rotational shift throughout the 198° and frame
averaging value set at 2. Obtained images were reconstructed
using NRecon (Bruker) and the quantiﬁcation was performed
using CTAn (Bruker) software. For quantiﬁcation of the
medullary canal volume, the defect site was approximated
and delineated manually after which parameters for bone
volume (BV) and newly formed endosteal/medullary volume
(MV) were calculated. 3D models of the scanned bones were
obtained using CTVox (Bruker) software. Quantitative micro-CT
results were analyzed by one-way ANOVA with post hoc test for
linear trend.
Histology
Soft tissue free bones were ﬁxed in 4% formalin for 2 weeks, and
entire bone was embedded in plastic resin (Technovit 7200).
Samples were cut at 5mm slices with a diamond saw and
stained using Masson Goldner Trichrome dye, as previously
described.(50,51) Images were obtained using Olympus BX51 Epi-
Fluorescence microscope.
Data analysis
Values are expressed as mean SEM or SD as indicated. For
statistical comparison of two samples, a two-tailed Student’s t
test was used and p< 0.05 was considered signiﬁcant. Two-way
analysis of variance with Duncan’s multiple range test was
performed to determine the effect of treatment and time on
biochemical and bone repair parameters. Additional speciﬁc
data analyses are presented in ﬁgure legends. Analyses were
performed by SAS for Windows 9.3 (SAS Institute).
Results
rhBMP6 production and biological activity
rhBMP6 was produced as a secretory dimeric protein from a
stable CHO cell line generated by recombinant technology.(9,14)
rhBMP6 was puriﬁed to near homogeneity (>99%) from the
medium by subjecting to conventional ionic, hydrophobic, and
metal-chelated chromatography with ﬁnal reverse-phase C18-
HPLC columns. rhBMP6 behaves as a diffused 37 kDa in
nonreduced condition and 17 kDa under reduced condition, as
stained by Coomassie blue (Fig. 1A) and as cross-reacted species
by Western blot using BMP6-speciﬁc antibody (Fig. 1B). BMP6-
speciﬁc monoclonal antibody, which has been used for Western
blot, recognizes all forms of nonreduced protein and mostly the
larger form of reduced species. The biological activity of the
puriﬁed rhBMP6 was assessed by using mouse C2C12-estab-
lished myoblast cell line transfected with BMP Response
Elements (BRE)–Luciferase (Leu) construct at varying doses
(Fig. 1C).
rhBMP6 binding and release studies using blood
coagulum
Blood samples taken randomly from 60 human subjects
(referred to Department of Laboratory Diagnostics of University
Hospital Center Zagreb) demonstrated that 75% of samples
coagulated in 30 minutes, and 100% of samples achieved
coagulation in 60minutes from blood sampling (Fig. 2A). Studies
with radioactive technetium (99mTc)-labeled rhBMP6 performed
to evaluate the extent of rhBMP6 binding to coagulum show
that more than 99% of 99mTc-rhBMP6 was retained in the
coagulum at 30, 45, and 60 minutes after mixing with blood.
Examination of the ratio of released/retained rhBMP6 from the
blood coagulum over a 14-day period shows that it is released
slowly from the coagulum with a mean residence time of
approximately 5 to 7 days as determined by a speciﬁc ELISA
(Fig. 2B). The analysis of the stability of rhBMP6 during the
preparation of ABGS demonstrated no signs of degradation after
60 to 90 minutes and overall loss in syringes was around 5% as
examined by Western blot (Fig. 2C). Studies on binding and bio-
distribution of rhBMP6 to blood proteins using radio-labeled
rhBMP6, dot-blot, and immunoblot analysis demonstrated
that more than 95% of the rhBMP6 was captured within
the coagulum and sequestered to blood components like
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Fig. 1. Puriﬁcation and biological activity of rhBMP6. SDS-PAGE analysis of rhBMP6: Coomassie-stained (A) and Western blot (B). Nonreduced (37 kDa)
forms are presented in lanes 1 and 6 and reduced (17 kDa) forms are in lanes 2 and 5, respectively. Molecular weightmarker (ColorBurst, Sigma-Aldrich) is
indicated in lanes 3 and 4, respectively. (C) Speciﬁc rhBMP6 activity in C2C12-BRE-Luc reporter gene assay: comparison between two different clinical
batches. The activity was tested in a range of concentrations as in x axis and expressed in relative light units (RLU) as in y axis. Data representmean SEM
of 3 independent measurements.
Fig. 2. Characterization of coagulation and binding, release, and stability of rhBMP6 in autologous bone graft substitute (ABGS). (A) Cumulative
frequency of coagulation formation over time. Raw data (n/N) and percentages are shown. Bracketed values are exact 95% conﬁdence intervals (left-
sided 97.5% at 60 minutes). (B) Release proﬁle of rhBMP6 from ABGS using two different concentrations of rhBMP6 over a 14-day period, as determined
by ELISA. Data represent mean SEM of 3 independent measurements. (C) The stability of rhBMP6 during preparation of the ABGS implant was
maintained over 60 minutes (lane 4) and 90 minutes (lane 5) with a loss of around 5% during preparation (lane 3). Arrow indicates35 kDa band, which
corresponds to the mature rhBMP6 under nonreduced condition. (D) Semiquantitative analysis of 99mTc-labeled rhBMP6 binding to blood components
in a dot blot assay. Meanþ SEM (n¼ 3) are shown.
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ﬁbrinogen, alpha 2-macroglobulin, beta-2-microglobulin, and
thrombin (Fig. 2D). A high level of rhBMP6 saturation (99.9%)
was achieved within coagulum and the release of rhBMP6 from
the coagulum within the ﬁrst 24 hours was lower than 0.2%.
Examination of the time to achieve the formation of ABC
consistently with deﬁned rheological properties (stiffness,
elasticity, and work load) suggests a requirement of 45 to 60
minutes (Fig. 3) to achieve a uniform coagulation, and it
maintained its shape for 5 days, then reduced its size, dimension,
and consistency at day 8 and dissolved by day 14. Although all
the results described here are obtained using human blood
samples, comparable ﬁndings were observed for rat and rabbit
blood coagulum (data not shown).
Biological activity of ABGS at rat subcutaneous sites
The biological activity of ABGS was assessed in the rat
subcutaneous implantation assay. The formation of endochon-
dral bone was examined at days 1, 2, 3, 7, and 35 post-
implantation by histology and micro-CT analyses. Fig. 4A shows
the photomicrographs of ABC alone implants harvested at days
1, 3, and 7. ABC alone formed a solid pluglike implant on day 1
surrounded by a thin membrane of extracellular matrix and
external mononuclear cells. Inside ABC, a layer of mesenchymal
osteoprogenitor-like cells formed a zone that toward day 3
merged with external cell condensations. By day 7, the ABC
showed the sign of dissolution and was replaced by normal
connective tissue without evident inﬂammation, ﬁbrosis, or
edema, and by day 35, it completely disappeared with no sign of
the implant visible. The absence of inﬂammatory cells and no
granuloma tissue was noted. Fig. 4B shows the photomicro-
graphs of ABC with rhBMP6 (25mg/implant) implants harvested
at days 1, 3, 7, and 35. Day 1 implant composed of
osteoprogenitor cells (mesenchymal stem cells [MSCs]) stained
positive for alkaline phosphatase. By day 3, MSCs underwent
condensation with extracellular matrix expansion and sign of
early chondrocytes within the “osteoprogenitor zone” slowly
penetrated by cells from outside the ABC. This interconnected
area of ABC composed of MSCs under the rhBMP6 inﬂuence
rapidly differentiated into chondrocytes. By day 7, differentiated
chondrocytes underwent hypertrophy, resulting in endochon-
dral bone formation. By day 35, a dense trabecular bone was
evident with a broad outside cortexlike structure. The cellular
response elicited by ABGS (rhBMP6/ABC) was compared with
rhBMP2/Bovine Absorbable Collagen Sponge and rhBMP7/
Bovine Bone Collagen implants at an early time point. The
Fig. 3. Mechanical properties of the coagulum stiffness (N), elasticity (mm), andwork load. (A) The effect of time. LS¼ least squares (mean). (B) The effect
of hemolysis. p< 0.025 considered statistically signiﬁcant (Q1, Q3–quartiles). (C) The effect of CaCl2.
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degree of inﬂammation, as determined by neutrophil accumu-
lation and myeloperoxidase activity (MPO), on day 3 implants
suggests that ABGS had a reduced neutrophil accumulation
(Fig. 4C) and a lower total MPO activity (Fig. 4D) compared with
BMP2- or BMP7-containing xenogeneic collagen implants.
Macroscopically, visualization after removal of implants from
the rat’s axilla is shown in Fig. 5A and indicates absence of a
ﬁbrous capsule. Quantiﬁcation of the ectopic bone formation as
represented as bone volume (BV) showed a dose response,
assessed by micro-CT analysis (Fig. 5B).
Evaluation of ABGS in rabbit ulna defect models
The ABC implanted alone did not result in the formation of new
bone and failed to achieve rebridgement of the defect (Fig. 6).
ABC containing rhBMP6 (ABGS), however, reproducibly induced
new bone formation and restored the defect as assessed by
radiography. The new bone formation was induced in a dose-
dependent manner as represented at weeks 6, 9, 13, 16, 19, and
23 (Fig. 6), and all rabbit ulna are shown at the week 23
(Fig. 7A–C). Micro-CT analyses showed a dose-dependent
increase in bone quantity as examined by bone volume (BV)
and medullary volume (MV), which are comparable to the intact
bone of the contralateral side (Fig. 7D). The bone quality was
further conﬁrmed by histology, as shown in a representative
sample from each group (Fig. 8). The dose of 100mg rhBMP6/mL
ABC resulted in the complete restoration with fully established
cortices and remodeledmedullar canal. In three rabbits, a partial
synostosis between healed ulna and radius appeared due to the
lack of space separating the two bones (Fig. 7B). The limitation of
the current study is a lack of biomechanical analysis as we have
dedicated most of the animals for the radiographic, micro-CT,
and histologic analyses.
ABGS versus rhBMP7/bovine collagen
We compared side-by-side rhBMP7/bovine bone collagen
device with the ABGS (rhBMP6/ABC) device in the rabbit ulna
defect repair model. Collagen alone did not induce bone
formation (data not shown), but rhBMP7 containing collagen
induced new bone formation (Fig. 9A). The rhBMP7/bovine bone
collagen commercial device contains 3.5mg rhBMP7/g of
collagen, and to ﬁll the rabbit ulna defect, we used 300mg
that accounts for the total amount of 1.06mg rhBMP7 in a
Fig. 4. Evaluation of ABGS in rat subcutaneous implants harvested at days 1, 3, 7, and 35. (A) Photomicrographs of histology of ABC alone at days 1, 3, and
7. Size marker: left column 500mm (magniﬁcation 4); middle column 200mm (magniﬁcation 10); right column upper (top) image 20mm
(magniﬁcation 60) and middle and lower (bottom) image 50mm (magniﬁcation (40). (B) Photomicrographs of histology of ABGS (25mg rhBMP6 per
implant) at days 1, 3, 7, and 35. Size marker: left column 500mm (magniﬁcation 4); middle column upper (top) and lower (bottom) image 200mm
(magniﬁcation 10), middle images 500mm and 200mm (magniﬁcation 4 and 10, respectively); right column upper (top) image 20mm
(magniﬁcation 60) and middle and lower (bottom) images 50mm (magniﬁcation 40). Asterisks denote clearly demarcated zone composed of
osteoprogenitor cells stained positive for alkaline phosphatase on day 1; with condensations of extracellular matrix (black arrows) and formation of early
chondrocytes within the osteoprogenitor zone (black arrowheads). On day 3, cells from outside the ABC slowly penetrated and hypertrophic
chondrocytes in endochondral bone formation appeared on day 7 (yellow arrowheads). On day 35, dense trabecular bone (yellow arrows) with a broad
cortexlike structure from outside demonstrated a solid persistent bone ossicle (green arrowhead). (C) The neutrophil inﬁltration on histological sections.
The implants were examined on day 3 after implantation of 20mg rhBMP2/300mg bovine Achilles tendon, 20mg rhBMP7/300mg bovine bone collagen
carrier, or 20mg rhBMP6/300mL ABC, respectively. Mean SEM (n¼ 10), p< 0.01 versus rhBMP6, p< 0.05 versus rhBMP6. (D) Myeloperoxidase (MPO)
activity. Mean SEM (n¼ 8), p< 0.01 versus rhBMP6, p< 0.05 versus rhBMP6.
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collagen carrier. This rhBMP7/collagen-induced rebridgement of
the ulna defect was compared with ABGS (100mg rhBMP6 in
1.5mL blood) as shown in Fig. 9A. ABGS induced, at weeks 2 and
6, a formation of a new uniform bone and underwent a
remodeling to rebridge new cortices with adjacent host bone,
whereas the bone formation with rhBMP7/collagen was
delayed. Micro-CT analysis conﬁrmed that the ABGS containing
rhBMP6 induced on week 8 after surgery around 2more bone
volume (Fig. 9B, C). The differential sensitivity to increasing
concentration of Noggin was tested in the C2C12 cell assay, in
which rhBMP6 (5mg) was resistant to Noggin-mediated
inhibition compared with rhBMP7 (5mg) (Fig. 9D).
Discussion
Bone morphogenetic proteins have been extensively explored
for their remarkable potential to regenerate new bone at
ectopic(13) and orthotopic sites.(52) Among BMPs, BMP2 and
BMP7 have been used in various clinical studies to promote
bone formation both in orthopedic(21,53) and dental(54–56)
applications; however, safety issues and limitation in their use
were reported.(57–59) The bone devices consisting of a bovine
collagen matrix soaked with rhBMP2 or rhBMP7(60,61) were
approved by regulatory agencies for the treatment of tibial
fractures and nonunions but have also been used off-label for
different bone repair indications with an aim to overcome the
impaired healing.(61,62)
In the present study, we demonstrate that an autologous
bone graft substitute containing rhBMP6 delivered within
autologous blood coagulum is capable of inducing new bone
formation in rat subcutaneous implants and can rebridge a large
segmental defect in ulna of mature rabbits. BMP6 was chosen
because it does not bind avidly to Noggin,(63) a natural BMP
antagonist abundant in bone and induces downstream
Fig. 5. Rat subcutaneous implants. (A) Rat subcutaneous implants in
vivo. The white arrow indicates the implant; white circle shows lack of
ﬁbrotic tissue accumulation. (B) Bone volume (BV) calculated after micro-
CT scan in rat subcutaneous implants at day 35 with various rhBMP6
doses and accompanying 3D models of the newly formed bone. The
rhBMP6 dose used is represented as mg/implant. Mean SEM (n¼ 4 per
dose), p< 0.01 versus 2.5mg, 5mg, and 10mg; p< 0.05 versus 2.5mg.
Fig. 6. Radiographs of bone healing through the course of 0 to 23weeks
for different doses of rhBMP6 (0, 25, 50 and 100mg). Representative
rabbit from each treatment group is presented.
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Fig. 7. The effect of rhBMP6 dose on bone healing in rabbit ulna segmental defect. (A) Radiographs of all bone samples (n¼ 5 per group) at week 23. (B)
Radiographic grading scores (0–6) of all bone samples using an established scoring system.(38,39) (C) 3Dmodels (longitudinal and cross-sectional) of bone
healing in rabbits after ex vivo micro-CT scan at week 23 after study termination. Three bone samples per dose group are shown, with corresponding X-
ray image on the left. Yellow arrows indicate initial defect size and introduced bone osteotomy sites. White asterisk indicates a partial synostosis between
ulna and radius. (D) Quantitative analysis of newly formed bone revealed a dose-dependent manner of rhBMP6 stimulation of bone defect healing. For
quantiﬁcation, the defect site was approximated and delineated manually after which parameters for bone volume (BV) and newly formed endosteal/
medullary volume (MV) were calculated. 3D models of the scanned bones were obtained using CTVox (Bruker) software. Quantitative micro-CT
parameters were analyzed by one-way ANOVA with post hoc test for linear trend. Each bar represents mean SD.
39 of 13-%05 3OXV :2$ BMP6 DELIVERED WITHIN ABC AS A BONE GRAFT SUBSTITUTE
signaling by spanning across most of the BMP type I and type II
receptors that are present on the cell surface of responding
osteoprogenitors.(64) These BMP6 biological characteristics
support a high speciﬁc alkaline phosphatase activity in cultures
of established C2C12 mouse cell line(41) and rat osteosarcoma
osteoblastic cell line, ROS 17/2.8, compared with other BMPs
examined.(63)
A wide range of carriers for BMPs have been investigated for
orthopedic indications comprising polymers (synthetic and of
natural origin), inorganic materials, and composites ranging
from nanoparticles to complex three-dimensional scaffolds,
membranes for tissue-guided regeneration, biomimetic surfa-
ces, and smart thermosensitive hydrogels.(65,66) Carrier systems
sustain the concentration of the rhBMP at the treatment site,
provide temporary scaffolding for osteogenesis, prevent ectopic
bone formation, and are ultimately absorbed over time.
Autologous blood coagulum was choosen as a preferred
scaffold because it provides: 1) ﬁbrin meshwork for rhBMP6 to
bind tightly and release it slowly as intact protein over 6 to
8 days; 2) circulating osteoprogenitors for rhBMP6 to respond
readily during the fabrication of coagulum; and 3) a permissive
environment provoking lesser inﬂammation and devoid of
immune response. In ABGS, most (>95%) of rhBMP6 added to
autologous blood bound tightly to plasma proteins in the
coagulum, including albumin, thrombin, heparan sulfate, and
others. The addition of lower amounts of CaCl2 ensured that the
coagulum remains homogeneous, cohesive, syringeable, in-
jectable, and malleable. The time required to achieve the
deﬁned physical characteristic of the coagulum appears to be in
the range of 45 to 60 minutes. The time to achieve a uniform
coagulation of ABC was determined based on the rheological
properties (elasticity, stiffness) preferred for injection or
implantation to assure a shape at the pocket of segmental
defect. This was supported by the coagulum formation over
time in human population where 60 minutes provided a safer
and more reliable time frame for obtaining implant of desired
and necessary quality characteristics (Fig. 2A).
In the rat subcutaneous assay, rhBMP6/ABC induces the
cascade of cellular events that result in endochondral new bone
formation histologically comparable to that of rhBMP2 or
rhBMP7 with rat allogenic bone collagen as carrier and/or
allogenic DBM(13,67,68) with an accelerated chondrogenesis and
osteogenesis as examined at various time intervals after the
implantation. The newly formed bone undergoes a typical
remodeling that results in ossicles containing functional bone
marrow elements with cortices surrounding the implant outer-
space and fully maintained the volume of the implant by day 35.
The use of ABGS in the subcutaneous assay resulted in absence
of inﬂammation and immune responses compared with animal-
derived collagen as shown by a lower neutrophil accumulation
and lower total MPO activity.
ABGS (rhBMP6/ABC) induced new bone formation in rabbits
and restored ulna critical size defects in a dose-dependant
manner, as examined by ex vivo radiographs. The dose of
100mg/mL ABC induced an optimal bone formation, whereas
25mg/mLABC showed a lesser response and at 50mg/mL of ABC
showed an intermediate response. The ABGS-induced bone
formation is directly proportional to the dose used and this
dose-dependent response is comparable both in rat subcutane-
ous implants and rabbit ulna segmental defect models, as has
previously been shown for rhBMP2 in a gap healing defect
canine model.(69) A comparative study with rhBMP7/collagen
sponge showed that ABGS induced a new bone that is restricted
to the defect area and undergoes remodeling to achieve a
complete union quality comparable with native bone. Although
preclinical studies have limitations as no given animal model
mimics human skeletal and biomechanical conditions in
entirety,(39) diaphyseal segmental defect in preclinical studies
served as measurable outcome for bone formation toward
clinical studies.(70) One of the drawbacks of studies in small
animal models (rodents and rabbits) is retaining of notochordal
cells in adult life, so the regenerative effect of BMPs may be
different from that observed in humans.(21) Another limitation is
that four-legged animal loading and precise musculoskeletal
structure is mechanically dispositioned compared with humans.
The appearance of synostosis between ulna and radius was
observed in three rabbits, which reﬂects the nature of
osteogenic BMPs to induce bone formation and fusion upon
contact with new and old bone as the space of separation
between the ulna and radius is smaller in rabbits than
humans.(39)
In summary, we present an ABGS that contains a low dose of
rhBMP6 delivered within ABC, a biocompatible native scaffold,
and may serve as a safe and robust biological osteoinductive
device, which is in contrast to other BMP-based therapies
Fig. 8. Evaluation ABGS in ulna critical size defect in rabbits. (A)
Photomicrographs of histology of representative slides from animals
treated with rhBMP6. Rabbits treated with 100mg rhBMP6 showed a
complete restoration with cortical and trabecular bone in the diaphysis
and rabbits treated with 50mg rhBMP6 showed a complete healing with
delayed remodeling, while rabbits treated with 25mg rhBMP6 showed
an incomplete rebridgement of bone defect showing a dose-dependent
effect at 23 weeks after surgery. Yellow arrowheads denote the size of
surgical defects. (B) Magniﬁed section of newly formed bone from yellow
rectangles in A. Black arrowheads indicate blood vessels, and arrows
indicate enlarged osteocyte lacunae in the new woven bone under
remodeling. Size marker indicates 200mm.
10 of 13 -%05 3OXV :2$GRGUREVIC ET AL.
(rhBMP2 and rhBMP7), employing bovine Achilles tendon and
bone-derived collagen, respectively, and a high BMP dose. More
preclinical studies and subsequent evaluation is ongoing,(71) and
future clinical trials are needed to address the safety and efﬁcacy
of ABGS (rhBMP6/ABC)-based bone graft implant for its potential
use in orthopedic patients.
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